Related Experiment Videos
Cell death regulation during multistep lymphomagenesis
B Hsu1, M C Marin, T J McDonnell
1Department of Molecular Pathology, University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA.
Cancer Letters
|July 20, 1995
Summary
Genetic alterations in malignant lymphomas, including c-myc, bcl-2, and p53 genes, were studied in mice. These genes regulate apoptosis and contribute to lymphomagenesis, suggesting therapeutic potential.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Malignant lymphomas often involve genetic abnormalities affecting key oncogenes and tumor suppressors.
- Common genetic alterations include deregulated expression of c-myc and bcl-2 oncogenes and p53 tumor suppressor gene inactivation.
Purpose of the Study:
- To investigate the role of c-myc, bcl-2, and p53 in regulating apoptosis and lymphomagenesis.
- To examine the combined effects of these genetic alterations in vivo.
- To discuss the therapeutic implications of inducing apoptosis.
Main Methods:
- Utilized genetically engineered mouse models: bcl-2-Ig and E mu-myc transgenic mice, and p53 knockout mice.
- Prospectively analyzed the regulation of apoptotic cell death.
- Studied the contribution of genetic alterations to in vivo lymphomagenesis.
Main Results:
- Demonstrated the critical roles of c-myc, bcl-2, and p53 in controlling apoptosis.
- Showcased how combined genetic alterations accelerate lymphomagenesis in mice.
- Provided insights into the mechanisms of lymphoma development.
Conclusions:
- Genetic alterations in c-myc, bcl-2, and p53 are central to malignant lymphoma pathogenesis.
- Understanding these pathways is crucial for developing targeted therapies.
- Therapeutic induction of apoptosis holds promise for lymphoma treatment.